OncoMatch/Clinical Trials/NCT05320588
A Study in Patients With Advanced Cancers
Is NCT05320588 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including BIO-106 and Pembrolizumab for advanced cancer.
Treatment: BIO-106 · Pembrolizumab — A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Cardiac function
Impaired cardiac function or history of clinically significant cardiac disease [excluded]
Impaired cardiac function or history of clinically significant cardiac disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- NEXT Oncology Austin · Austin, Texas
- University of Texas MD Anderson Cancer Center · Houston, Texas
- NEXT Oncology Virginia · Fairfax, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05320588 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify